A Single-Blind, Randomized, Placebo-Controlled, Ascending Single Dose and Repeat Dose Study With Once Daily Dosing To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 in Healthy Overweight and Obese Subjects
Latest Information Update: 23 Jun 2023
At a glance
- Drugs GSK 376501 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GSK
- 12 Jul 2007 New trial record.